Maximizing the Benefits of Targeted Cancer Treatment with PI3K Inhibitors

Released On
August 15, 2020

Expires On
August 14, 2022

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Practicing Clinicians Exchange.

This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.

This activity is supported by an educational grant from Verastem Oncology.

Credit Available

  • CE/CME Credit Hours: 1.00
  • Pharmacology Credit Hours: 1.00

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Significant advances in targeted and immunotherapies in recent years have revolutionized the treatment of cancer. Among the new therapeutic options are the phosphatidylinositol-3-kinase (PI3K) inhibitors, which have demonstrated efficacy in both hematologic malignancies and solid tumors, albeit at the price of a high risk of serious adverse effects. To date, the US Food and Drug Administration has approved four drugs in this class for treating cancer—alpelisib, copanlisib, duvelisib, and idelalisib. This online activity will focus on the role of PI3K in hematologic malignancies, the importance of PI3K inhibitors in treating these diseases, and methods of harnessing the therapeutic benefit of these drugs while minimizing and managing their toxicities.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the mechanism of action of PI3K inhibitors and their place in the cancer-treatment paradigm
  • Identify recommended strategies for management of adverse effects associated with PI3K inhibitors
  • Implement measures, including patient education, to monitor for and manage adverse effects associated with PI3K inhibitors



Matthew S. Davids, MD, MMSc

Assistant Professor of Medicine
Harvard Medical School
Director, DFCI Lymphoma Biobank
Associate Director, CLL Center
Dana-Farber Cancer Institute
Boston, Massachusetts


Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts


Accreditation Statement

In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit


AAPA Credit Designation

Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.



Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Matthew S. Davids, MD, MMSc

  • Consultant: Adaptive Biotechnologies, Beigene, Celgene, Janssen, Research to Practice, Zentalis
  • Consultant/Research Support: AbbVie, Ascentage Pharmaceuticals, AstraZeneca, Genentech, MEI Pharmaceuticals, Pharmacyclics, TG Therapeutics, Verastem
  • Research Support: Surface Oncology

Josie Montegaard, MSN, AGPCNP-BC

  • Advisory Board: AstraZeneca, Pharmacyclics
  • Expert Panel: Janssen

Corinne Williams, PA-C

  • Speakers Bureau: AstraZeneca

Instructions for Participation and Credit

Participants wishing to earn CE/CME credit must:

  1. Read the content in its entirety.
  2. Relate the content material to the learning objectives.
  3. Complete the post-test and evaluation form.
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact